Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus + lactobacillus acidophilus
- Development stage
- Unknown
- Lead developer
- Giellepi
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Vaginal
01
Overview
Lactobacillus rhamnosus + Lactobacillus acidophilus is a probiotic combination drug composed of two live bacterial strains—Lactobacillus rhamnosus and Lactobacillus acidophilus—as its active ingredients. It is classified as a live biotherapeutic product and microbial therapy. One prominent branded formulation is Respecta, which specifically utilizes the strains L. rhamnosus HN001 and L. acidophilus La-14, often in conjunction with lactoferrin. The combination is designed to restore and maintain a healthy microbiome in the gut and vaginal tract. Its mechanism of action involves colonizing mucosal surfaces, producing lactic acid to maintain an acidic environment that inhibits pathogens like Gardnerella vaginalis, and modulating host immune responses by inhibiting pro-inflammatory pathways such as NF-κB and reducing levels of cytokines like IL-1β and TNF-α. It has been clinically investigated for the treatment of bacterial vaginosis, ulcerative colitis, and the prevention of antibiotic-associated diarrhea.
- Brand names
- Respecta
- Other names
- L. rhamnosus + L. acidophilusLactobacillus rhamnosus HN001 + Lactobacillus acidophilus La-14
02
Targets
TLR2 (Toll-like Receptor 2)IL1B (Interleukin-1 beta)VMC (Vaginal/urogenital microbiome community)TLR4 (Toll-like receptor 4)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on lactobacillus rhamnosus + lactobacillus acidophilus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus + lactobacillus acidophilus.